Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors
Advanced Science · 2023-03 · 10 (7)
DOI: 10.1002/advs.202205262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.01.2023. Verfasst von Si-Qi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GuangDong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Glutathione S‐transferase pi (GSTP1), a phase II detoxification enzyme, is known to be overexpressed and mediates chemotherapeutic resistance in lung cancer. However, whether GSTP1 supports cancer stem cells (CSCs) and the underlying mechanisms in lung adenocarcinoma (LUAD) remain largely unknown. This study unveiled that GSTP1 is upregulated in lung CSCs and supports tumor self‐renewal, metastasis, and resistance to targeted tyrosine kinase inhibitors of LUAD both in vitro and in vivo. Mechanistically, CaMK2A (calcium/calmodulin‐dependent protein kinase 2 isoform A)/NRF2 (nuclear factor erythroid 2‐related factor 2)/GSTP1 is uncovered as a regulatory axis under hypoxia. CaMK2A increased GSTP1 expression through phosphorylating the Sersine558 residue of NRF2 and promoting its nuclear translocation, a novel mechanism for NRF2 activation apart from conventional oxidization‐dependent activation. Upregulation of GSTP1 in turn suppressed reactive oxygen species levels and supported CSC phenotypes. Clinically, GSTP1 analyzed by immunohistochemistry is upregulated in a proportion of LUAD and serves as a prognostic marker for survival. Using patient‐derived organoids from an ALK ‐translocated LUAD, the therapeutic potential of a specific GSTP1 inhibitor ezatiostat in combination treatment with the ALK inhibitor crizotinib is demonstrated. This study demonstrates GSTP1 to be a promising therapeutic target for long‐term control of LUAD through targeting CSCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.
- Department of Pathology, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, 999077, China.
- Institute for Stem Cell and Regenerative Medicine, Chinese Academy of Sciences, Beijing, 100101, China.
- Bejing Institute for Stem Cell and Regenerative Medicine, Beijing, 100101, China.
- Department of Physiology, School of Medicine, Jinan University, Guangzhou, 510000, China.
- Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong SAR, 999077, China.
ORCID-Profile: Si-Qi Wang, Ye Chun Ruan, Judy Wai Ping Yam, Zhi-Jie Xiao
Förderung
- GuangDong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wang, S. Q., Chen, J. J., Jiang, Y., Lei, Z. N., Ruan, Y. C., Pan, Y., Yam, J. W. P., Wong, M. P., & Xiao, Z. J. (2023). Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors. Advanced Science, 10(7). https://doi.org/10.1002/advs.202205262
Vancouver
Wang SQ, Chen JJ, Jiang Y, Lei ZN, Ruan YC, Pan Y, et al. Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors. Advanced Science. 2023;10(7). doi:10.1002/advs.202205262
BibTeX
@article{Wang2023,
author = {Wang, Si-Qi and Chen, Jun-Jiang and Jiang, Yuchen and Lei, Zi-Ning and Ruan, Ye Chun and Pan, Yihang and Yam, Judy Wai Ping and Wong, Maria Pik and Xiao, Zhi-Jie},
title = {Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {7},
doi = {10.1002/advs.202205262}
}
EUVIMED